Dánia - dán - Lægemiddelstyrelsen (Danish Medicines Agency)

paranova danmark a/s - baclofen - tabletter - 10 mg

Dánia - dán - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - ethinylestradiol, gestoden - overtrukne tabletter - 75+20 mikrogram

Dánia - dán - Lægemiddelstyrelsen (Danish Medicines Agency)

paranova danmark a/s - baclofen - tabletter - 25 mg

Európai Unió - dán - EMA (European Medicines Agency)

recordati rare diseases - osilodrostat fosfat - cushing syndrome - kortikosteroider til systemisk brug - isturisa er indiceret til behandling af endogene cushings syndrom hos voksne.

Dánia - dán - Lægemiddelstyrelsen (Danish Medicines Agency)

hameln pharma gmbh - furosemid - injektionsvæske, opløsning - 10 mg/ml

Európai Unió - dán - EMA (European Medicines Agency)

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - gastrointestinale stromale tumorer - antineoplastiske midler - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.

Európai Unió - dán - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - carcinom, ikke-småcellet lunge - antineoplastiske midler - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Európai Unió - dán - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - multipel sklerose, recidiverende-remitterende - immunosuppressiva - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Európai Unió - dán - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomide - multipel sklerose, recidiverende-remitterende - immunosuppressants, selektiv immunosuppressive - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Dánia - dán - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - teriflunomid - filmovertrukne tabletter - 14 mg